CoChat

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Open access
Michos, Erin D., Lopez‐Jimenez, Francisco, Gulati, Martha · 2023 · Journal of the American Heart Association
Cited by 90

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity‐related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevention of CVD in patients with overweight or obesity. The recently demonstrated efficacy of some pharmacologic therapies for chronic weight management may encourage health care professionals to recognize obesity as a treatable serious chronic disease and motivate patients to re‐engage with weight loss when previous attempts have been ineffective or unsustainable. This review article summarizes the benefits and challenges associated with lifestyle changes, bariatric surgery, and historical pharmacologic interventions in the treatment of obesity, and focuses on the current evidence for the efficacy and safety of the newer glucagon‐like peptide‐1 receptor agonist medications in the management of obesity and potential reduction of CVD risk. We conclude that the available evidence demonstrates glucagon‐like peptide‐1 receptor agonists should be strongly considered in clinical practice for the treatment of obesity and reduction of CVD risk in people with type 2 diabetes. If ongoing research proves glucagon‐like peptide‐1 receptor agonists to be effective in reducing the risk of CVD onset in patients with obesity, irrespective of type 2 diabetes status, it will herald a new treatment paradigm in this setting, and now is the time for health care professionals to better recognize the benefits of these agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.122.029282

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 28

  1. 10.1038/s41366-021-00788-4 · DOI · Paper page
  2. 10.1161/JAHA.121.022930 · DOI · Paper page
  3. 10.1093/europace/euy117 · DOI · Paper page
  4. 10.1093/fampra/cmab169 · DOI
  5. 10.2337/ds017-0025 · DOI · Paper page
  6. 10.1093/eurheartj/ehac071 · DOI · Paper page
  7. 10.1001/jamasurg.2020.0087 · DOI · Paper page
  8. 10.1016/j.jviscsurg.2017.10.012 · DOI
  9. 10.1093/bjs/znab245 · DOI
  10. 10.1007/s11883-014-0445-x · DOI
  11. 10.1093/ajcn/80.6.1461 · DOI
  12. 10.1177/2042018819897527 · DOI
  13. Sherman MM, Ungureanu S, Rey JA. Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. PT. 2016;41:164–172.
  14. 10.3945/ajcn.111.024927 · DOI · Paper page
  15. 10.1038/ijo.2016.67 · DOI · Paper page
  16. 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5 · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
  17. 10.1056/NEJMoa1901118 · DOI · Paper page
  18. 10.1056/NEJMoa1612917 · DOI · Paper page
  19. 10.1161/CIRCULATIONAHA.118.036811 · DOI
  20. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  21. 10.1016/j.pcad.2017.09.001 · DOI
  22. 10.1016/S0140-6736(97)11509-4 · DOI · Paper page
  23. 10.1016/j.jdiacomp.2020.107548 · DOI
  24. 10.1038/sj.ijo.0802831 · DOI
  25. 10.1016/j.ahj.2010.07.023 · DOI
  26. 10.2337/dc20-2977 · DOI · Paper page
  27. 10.1161/JAHA.121.023811 · DOI · Paper page
  28. Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. JAMA. 2021;10:e021084.

Cited by

See all 90

Metadata

Authors
Michos, E. D., Lopez‐Jimenez, F., & Gulati, M.
Venue
Journal of the American Heart Association
Published
2023-06-06
Volume
12
Issue
11
Pages
e029282-e029282
ISSN
2047-9980 (ISSN-L)
OpenAlex
W4379508812
Cited by
90
References
68
FWCI
11.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. https://app.cochat.ai/papers/10.1161/jaha.122.029282
The paper
Michos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023). Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.029282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.